Does it all ADA up? Adalimumab for ulcerative colitis

被引:3
|
作者
Travis, Simon [1 ]
机构
[1] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford OX3 9DU, England
关键词
ACTIVITY INDEXES; THERAPY; INFLIXIMAB; DISEASE;
D O I
10.1136/gut.2010.233403
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:741 / 742
页数:2
相关论文
共 50 条
  • [41] Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany
    Poellinger, Bernadette
    Schmidt, Wolfgang
    Seiffert, Anna
    Imhoff, Heidi
    Emmert, Martin
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (02) : 195 - 203
  • [42] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [43] Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis
    Colombel, J. -F.
    Sandborn, W. J.
    Reinisch, W.
    Peyrin-Biroulet, L.
    Panaccione, R.
    Rutgeerts, P.
    Hanauer, S. B.
    Ghosh, S.
    Van Assche, G.
    Robinson, A. M.
    Lau, W.
    Maa, J. -F.
    Huang, B.
    Pappalardo, B.
    Read, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 219 - 228
  • [44] Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
    Gagnon, Ann-Lorie
    Beauchesne, William
    Tessier, Laurence
    David, Charles
    Berbiche, Djamal
    Lavoie, Alexandre
    Michaud-Herbst, Alban
    Tremblay, Karine
    CROHNS & COLITIS 360, 2021, 3 (04)
  • [45] Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
    Taxonera, Carlos
    Iglesias, Eva
    Munoz, Fernando
    Calvo, Marta
    Barreiro-de Acosta, Manuel
    Busquets, David
    Calvet, Xavier
    Rodriguez, Antonio
    Pajares, Ramon
    Gisbert, Javier P.
    Lopez-Serrano, Pilar
    Perez-Calle, Jose Luis
    Ponferrada, Angel
    De la Coba, Cristobal
    Bermejo, Fernando
    Chaparro, Maria
    Olivares, David
    Alba, Cristina
    Fernandez-Blanco, Ignacio
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (02) : 481 - 490
  • [46] Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes
    Christensen, Britt
    Hanauer, Stephen B.
    Gibson, Peter R.
    Turner, Jerrold R.
    Hart, John
    Rubin, David T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (10) : 1345 - 1353
  • [47] Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis?
    Moreira, Andre da Luz
    Vogel, Jon D.
    Baker, Mark
    Mor, Isabella
    Zhang, Ren
    Fazio, Victor
    JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (03) : 504 - 507
  • [48] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal B.
    GASTROENTEROLOGY, 2012, 142 (02) : 257 - +
  • [49] Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis
    Hussey, Mary
    Mc Garrigle, Robert
    Kennedy, Una
    Holleran, Grainne
    Kevans, David
    Ryan, Barbara
    Breslin, Niall
    Mahmud, Nasir
    McNamara, Deirdre
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 28 (02) : 217 - 221
  • [50] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Chen, Xinlin
    Hou, Jiangtao
    Yuan, Yujie
    Huang, Chaoyuan
    Liu, Tianwen
    Mo, Chuanwei
    Li, Haiwen
    Chen, Bin
    Xu, Qian
    Hou, Zhengkun
    He, Weiling
    Liu, Fengbin
    BIODRUGS, 2016, 30 (03) : 207 - 217